†rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

BUSINESS DESCRIPTIONMAIN PRODUCTSIn early 2001 Nycomed took over the marketing of Curosurf ® in the Nordic markets,Germany, Netherlands, Austria and Switzerland. Curosurf ® has existingannual sales in the Nycomed territory of about DKK 42 million and is the marketleader in Europe within its market segment.Curosurf ® is prescribed for prematurely born infants to prevent respiratory distress,a condition that will lead to death unless effectively treated. Curosurf ® isa lung surfactant developed by Chiesi Farmaceutici S.p.A. in Italy, where it wasfirst launched in 1992. It is sold in more than 30 countries worldwide.–29–